ScholarIQanswers from OpenAlex & ORCID
Pablo Winzer
ResearcherPublications, citations & collaboration network
Pablo Winzer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Pablo Winzer have?
ScholarIQindexed works
Pablo Winzer has 15 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Pablo Winzer have?
ScholarIQcitation count
Pablo Winzer has 433 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Pablo Winzer?
ScholarIQh-index
Pablo Winzer has an h-index of 12 in OpenAlex.
What is the i10-index of Pablo Winzer?
ScholarIQi10-index
Pablo Winzer has an i10-index of 12 in OpenAlex.
What is the OpenAlex record for Pablo Winzer?
ScholarIQopenalex
The OpenAlex for Pablo Winzer is on the source record.
What are the most-cited papers on Pablo Winzer?
ScholarIQmost cited works
<i>In Vitro</i> and <i>In Vivo</i> Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum
Pablo Winzer, Joachim Müller, Adriana Aguado-Martínez, Mahbubur Rahman, Vreni Balmer, Vera Manser, Luis Miguel Ortega‐Mora, Kayode K. Ojo, Erkang Fan, Dustin J. Maly, Wesley C. Van Voorhis, Andrew Hemphill
Neospora caninum Calcium-Dependent Protein Kinase 1 Is an Effective Drug Target for Neosporosis Therapy
Kayode K. Ojo, Molly C. Reid, Latha Kallur Siddaramaiah, Joachim Müller, Pablo Winzer, Zhongsheng Zhang, Katelyn R. Keyloun, Rama Subba Rao Vidadala, E.A. Merritt, Wim G. J. Hol, Dustin J. Maly, Erkang Fan, Wesley C. Van Voorhis, Andrew Hemphill
Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice
Joachim Müller, Adriana Aguado-Martínez, Vera Manser, Vreni Balmer, Pablo Winzer, Dominic Ritler, Isabel C. Hostettler, David Arranz-Solís, Luis Miguel Ortega‐Mora, Andrew Hemphill
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts
Dennis Imhof, Nicoleta Anghel, Pablo Winzer, Vreni Balmer, Jessica Ramseier, Kai Pascal Alexander Hänggeli, Ryan Choi, Matthew A. Hulverson, Grant R. Whitman, Samuel L.M. Arnold, Kayode K. Ojo, Wesley C. Van Voorhis, J. Stone Doggett, Luis Miguel Ortega‐Mora, Andrew Hemphill
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases
Wesley C. Van Voorhis, Matthew A. Hulverson, Ryan Choi, Wenlin Huang, Samuel L.M. Arnold, Deborah A. Schaefer, Dana P. Betzer, Rama Subba Rao Vidadala, Sangun Lee, Grant R. Whitman, Lynn K. Barrett, Dustin J. Maly, Michael W. Riggs, Erkang Fan, Thomas J. Kennedy, Saul Tzipori, J. Stone Doggett, Pablo Winzer, Nicoleta Anghel, Dennis Imhof, Joachim Müller, Andrew Hemphill, Ignacio Ferre, Roberto Sánchez-Sánchez, Luis Miguel Ortega‐Mora, Kayode K. Ojo